Guardant Health, Inc. (NASDAQ:GH) Stock Has Average Price Target of $190.00

Guardant Health, Inc. (NASDAQ:GH) has been assigned a consensus rating of “Moderate Buy” from the twenty-six brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, twenty-four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $190.40.

GH has been the subject of several research reports. Bank of America boosted their price objective on shares of Guardant Health from $135.00 to $190.00 and gave the company a “buy” rating in a report on Monday, July 6th. Stephens raised their target price on shares of Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Canaccord Genuity Group lifted their target price on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, Morgan Stanley boosted their target price on shares of Guardant Health from $185.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, October 12th.

Insider Transactions at Guardant Health

In other Guardant Health news, insider Terilyn J. Monroe sold 46,300 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total value of $7,645,056.00. Following the transaction, the insider owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. This represents a 66.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $169.58, for a total value of $10,786,135.90. Following the completion of the transaction, the insider directly owned 65,374 shares in the company, valued at $11,086,122.92. The trade was a 49.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 178,940 shares of company stock worth $30,070,911. Company insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Slow Capital Inc. lifted its stake in shares of Guardant Health by 0.3% in the 3rd quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock worth $9,397,000 after purchasing an additional 136 shares during the period. Kingswood Wealth Advisors LLC grew its position in Guardant Health by 46.1% during the third quarter. Kingswood Wealth Advisors LLC now owns 7,370 shares of the company’s stock valued at $1,315,000 after buying an additional 2,325 shares during the period. Ascent Wealth Partners LLC grew its position in Guardant Health by 11.6% during the third quarter. Ascent Wealth Partners LLC now owns 3,786 shares of the company’s stock valued at $675,000 after buying an additional 394 shares during the period. Gibbs Wealth Management grew its position in Guardant Health by 15.7% during the third quarter. Gibbs Wealth Management now owns 6,429 shares of the company’s stock valued at $1,147,000 after buying an additional 871 shares during the period. Finally, Sterling Capital Management LLC increased its holdings in Guardant Health by 204.3% during the third quarter. Sterling Capital Management LLC now owns 3,572 shares of the company’s stock valued at $637,000 after buying an additional 2,398 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $169.08 on Thursday. Guardant Health has a 1 year low of $68.02 and a 1 year high of $191.05. The company has a market cap of $22.69 billion, a P/E ratio of -48.45 and a beta of 1.58. The stock’s fifty day moving average price is $168.04 and its 200-day moving average price is $141.69.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. During the same quarter in the previous year, the business posted ($0.44) earnings per share. Guardant Health’s quarterly revenue was up 44.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Guardant Health will post -3.02 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.